<DOC>
	<DOCNO>NCT01883206</DOCNO>
	<brief_summary>The purpose study see well antibody level find month year patient enter previous randomise placebo-controlled trial glycoprotein B vaccine cytomegalovirus persist previous sample retested use different method develop different laboratory . Also , prepare monoclonal antibody B lymphocytes patient define strength . If potent antibody identify , investigator would like consider develop see protect future transplant patient cytomegalovirus .</brief_summary>
	<brief_title>CMV Glycoprotein B ( gB ) Vaccine Long Term Antibody Response</brief_title>
	<detailed_description>This follow study randomise control trial compare CMV glycoprotein B vaccine placebo ( Trial title : A Phase II Immunogenicity Trial Of Cytomegalovirus Glycoprotein B Vaccine In Allograft Candidate Recipients ; CTA ref 20363/0238/001-0010 ; REC ref 5476 ; UCL sponsor 05/009 ) participant Chronic renal liver deficiency sufficient require transplantation . The study provide encouraging result ( data unblinded analyse ) reduce amount cytomegalovirus vaccinate patient excrete blood post transplant ( Griffiths et al Lancet 2011 ) . The titre antibody make glycoprotein B correlate protection duration viraemia ( i.e . reduction CMV level ) . 100 % patient give vaccine produce antibody glycoprotein B although titre decreased time . The titre CMV neutralise antibody boost prior natural immunity . The titre neutralise antibody low among initially seronegative . However , improve assay CMV neutralise antibody become available , wish sample retested use different method . We also send blood sample take previous study lab enzyme immunoassay antibody glycoprotein B . This trial approach patient take part reference study one blood sample determine current antibody titre obtain consent test sample take previous study use new improve antibody assay . Monoclonal antibody make purified B lymphocyte study may bind neutralise cytomegalovirus laboratory order develop antibody potential therapeutic agent .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Recipient IMP ( Investigational Medicinal product ) ( CMV gB vaccine placebo ) trial 'Phase II Immunogenicity Trial Of Cytomegalovirus Glycoprotein B Vaccine In Allograft Candidate Recipients Study ' ( CTA ref 20363/0238/0010010 ; REC ref 5476 ; UCL sponsor 05/009 ) . 2 . Informed consent must obtain patient . 1 . Patient unable unwilling provide sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Cytomegalovirus</keyword>
</DOC>